Digital-first life sciences commercialisation company Indegene has announced its acquisition of medical writing consultancy Trilogy Writing & Consulting.
Trilogy is a Germany, UK and US-based provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
It has more than 22 years of experience in providing medical writing services to the biopharmaceutical and medical devices industry, with capabilities across a range of therapeutic areas, including oncology, immunology, neurosciences, urology, anti-infectives, endocrinology and respiratory diseases.
The acquisition of Trilogy by Indegene Ireland “augments Indegene’s depth of clinical and regulatory writing expertise for market authorisation applications globally,” the company said.
The medical writing market was $4.2bn in 2023 and is forecast to grow to $8.4bn by 2030, according to Grand View Research. However, Indegene notes that biopharma companies are “increasingly challenged” by a lack of internal expertise, continuous pressure on margins, and stringent expectations from regulatory authorities.
“Combining Trilogy’s expertise with Indegene’s capabilities, life sciences companies benefit from partnering with a single service provider to deliver effective medical writing expertise at scale across the value chain,” said Manish Gupta, Indegene’s chief executive officer.
He continued: “Our investments in content automation, especially leveraging generative artificial intelligence, will further improve outcomes for our clients in clinical and regulatory writing and even beyond.”
Indegene is focused on helping biopharmaceutical, emerging biotech and medical device companies develop products, get them to market and grow their impact through the life cycle.
Dr Julia Forjanic Klapproth, senior partner, Trilogy, said: “Joining the Indegene family is a testament to the quality of our services and the expertise of our specialist team. I am proud of Trilogy’s reputation and standing in the industry and look forward to the next stage of our development.”
Sharing a similar sentiment, Dr Lisa Chamberlain James, also senior partner at Trilogy, said: “This is an exciting and important evolution for Trilogy. We are confident that this partnership with Indegene will enable us to accelerate our growth and allow us to expand our tech-enabled medical writing services for the benefit of our life sciences clients.”